Trial Profile
A phase 2, randomized study of Velcade (bortezomib), dexamethasone, and thalidomide versus Velcade, dexamethasone, thalidomide, and cyclophosphamide in subjects with previously untreated multiple myeloma who are candidates for autologous transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Bortezomib; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Millennium
- 06 Nov 2019 A matching adjusted indirect comparison of the VTd-mod dose from recent clinical trials versus the dose included in the label was performed to understand the effect on efficacy of modified VTd dosing for patients with NDMM who are transplant eligible; results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 22 Oct 2012 Primary endpoint 'Near-complete-haematological-response-rate' has not been met.
- 23 Jun 2012 Additional locations (Czech Republic, France, Hungary, Italy, Portugal) added as reported by European Clinical Trials Database record.